February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
February 10, 2016 – An editorial from Peter A. Lio, MD on the Aron Regime.
February 3, 2016 – There are clear signs that what we eat can affect our skin, although for those with atopic dermatitis, there seem to be no easy answers. Is it possible that going gluten-free could improve or even cure eczema?
February 3, 2016 – Although atopic dermatitis (AD) usually improves with age, adults with a history of childhood AD often have persistent eczema on their hands and feet. While lots of people with eczema on their hands and/or feet have come up with their own tricks for keeping it under control, here are a few suggestions that can help.
December 11, 2015 – Retail prices of 19 brand-name prescription drugs for dermatologic conditions ranging from acne to cancer increased fivefold on average between 2009 and 2015, according to a study that adds new fuel to the burgeoning debate over the cost of medicines.
August 17, 2015 – The National Eczema Association (NEA) is pleased to share news about a potential new topical non-steroidal treatment for mild-to-moderate eczema that you, the National Eczema Association community, helped make possible.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.
July 10, 0215 – Eczema can be challenging any time of year. Here are some tips for managing eczema during the summer from people just like you, friends on NEA’s Facebook page.
May 7, 2015 – Researchers from St. Jude Children’s Research Hospital have identified a protein that offers a new focus for developing targeted therapies to tame severe inflammation. Targeting this protein has lead to a greater understanding on how mutations in a protein can lead to atopic dermatitis.